Beverly Mock
Laboratory of Cancer Biology and Genetics
The Center for Cancer Research
United States of America
Biography
Dr. Mock obtained her Ph.D. from the University of Maryland and continued her studies on the genetics of susceptibility to parasitic diseases in the Department of Immunology at the Walter Reed Army Institute of Research. Since coming to the NIH, she has focused her research on complex genetic traits associated with cancer initiation and progression in an effort to develop strategies for identifying and analyzing drug combinations to target susceptibility pathways.
Research Interest
Cancer Biology, Genetics and Genomics, Molecular Biology and Biochemistry, Molecular Pharmacology, Systems Biology
Publications
-
Constitutive reductions in mTOR alter cell size, immune cell development, and antibody production. Zhang S, Readinger JA, DuBois W, Janka-Junttila M, Robinson R, Pruitt M, Bliskovsky V, Wu JZ, Sakakibara K, Patel J, Parent CA, Tessarollo L, Schwartzberg PL, Mock BA. Blood. 117: 1228-38, 2011
-
B cell-specific deficiencies in mTOR limit humoral immune responses. Zhang S, Pruitt M, Tran D, Du Bois W, Zhang K, Patel R, Hoover S, Simpson RM, Simmons J, Gary J, Snapper CM, Casellas R, Mock BA. J. Immunol. 191: 1692-703, 2013.
-
TORC1 and class I HDAC inhibitors synergize to suppress mature B cell neoplasms. Simmons JK, Patel J, Michalowski A, Zhang S, Wei BR, Sullivan P, Gamache B, Felsenstein K, Kuehl WM, Simpson RM, Zingone A, Landgren O, Mock BA. Mol Oncol. 8: 261-72, 2014.
